NASDAQ:CMRX Chimerix (CMRX) Stock Price, News & Analysis $0.89 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.88▼$0.9150-Day Range$0.82▼$0.9952-Week Range$0.78▼$1.30Volume144,869 shsAverage Volume318,688 shsMarket Capitalization$79.77 millionP/E RatioN/ADividend YieldN/APrice Target$8.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Chimerix alerts: Email Address Chimerix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside855.1% Upside$8.50 Price TargetShort InterestHealthy2.00% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment1.10Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($1.03) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.36 out of 5 starsMedical Sector140th out of 936 stocksPharmaceutical Preparations Industry57th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageChimerix has received no research coverage in the past 90 days.Read more about Chimerix's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.00% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 7.1.Change versus previous monthShort interest in Chimerix has recently decreased by 11.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 2.8 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 1.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Chimerix this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have not sold or bought any company stock.Percentage Held by Insiders13.10% of the stock of Chimerix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions45.42% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Chimerix's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from ($0.85) to ($1.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioChimerix has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Chimerix's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Chimerix Stock (NASDAQ:CMRX)Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More CMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CMRX Stock News HeadlinesJuly 19, 2024 | americanbankingnews.comChimerix (NASDAQ:CMRX) Shares Pass Below Two Hundred Day Moving Average of $0.98July 5, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 30, 2024 | globenewswire.comChimerix to Participate in Fireside Chat at Jefferies Global Healthcare ConferenceMay 24, 2024 | barrons.comChimerix Inc.May 3, 2024 | markets.businessinsider.comBuy Rating Justified by Chimerix’s Upcoming Catalysts and Strong FinancialsMay 2, 2024 | markets.businessinsider.comStrong Buy Rating for Chimerix on Robust Financials and Promising Drug PipelineMay 2, 2024 | finance.yahoo.comChimerix, Inc. (NASDAQ:CMRX) Q1 2024 Earnings Call TranscriptJuly 26, 2024 | DTI (Ad)We’re in a code red crisis and 99% of Americans are clueless Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 2, 2024 | markets.businessinsider.comChimerix’s Strong Financials and Promising ONC201 Developments Merit Buy RatingMay 2, 2024 | finance.yahoo.comChimerix Inc (CMRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ...May 2, 2024 | au.finance.yahoo.comQ1 2024 Chimerix Inc Earnings CallMay 1, 2024 | msn.comChimerix GAAP EPS of -$0.25May 1, 2024 | sfgate.comChimerix: Q1 Earnings SnapshotMay 1, 2024 | globenewswire.comChimerix Reports First Quarter 2024 Financial Results and Provides Operational UpdateApril 30, 2024 | markets.businessinsider.comWhat Wall Street expects from Chimerix's earningsApril 24, 2024 | globenewswire.comChimerix to Report First Quarter 2024 Financial Results and Provide an Operational Update on May 1, 2024April 16, 2024 | globenewswire.comChimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees90Year Founded2000Price Target and Rating Average Stock Price Target$8.50 High Stock Price Target$11.00 Low Stock Price Target$6.00 Potential Upside/Downside+855.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,100,000.00 Net Margins-25,337.96% Pretax Margin-201,443.91% Return on Equity-41.32% Return on Assets-37.83% Debt Debt-to-Equity RatioN/A Current Ratio8.61 Quick Ratio8.61 Sales & Book Value Annual Sales$320,000.00 Price / Sales249.28 Cash FlowN/A Price / Cash FlowN/A Book Value$2.17 per share Price / Book0.41Miscellaneous Outstanding Shares89,630,000Free Float77,888,000Market Cap$79.77 million OptionableOptionable Beta1.20 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Michael T. Andriole M.B.A. (Age 51)CEO, President & Director Comp: $820kDr. Roy W. Ware MBAPh.D., Chief Manufacturing Technology OfficerKey CompetitorsFortress BiotechNASDAQ:FBIOscPharmaceuticalsNASDAQ:SCPHChiasmaNASDAQ:CHMAAquestive TherapeuticsNASDAQ:AQSTNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsAssenagon Asset Management S.A.Sold 49,759 shares on 7/18/2024Ownership: 0.452%Acadian Asset Management LLCBought 291,981 shares on 5/10/2024Ownership: 2.426%Koshinski Asset Management Inc.Bought 40,000 shares on 5/9/2024Ownership: 0.045%Marquette Asset Management LLCBought 22,709 shares on 5/7/2024Ownership: 0.129%Michael T AndrioleSold 1,744 sharesTotal: $1,813.76 ($1.04/share)View All Insider TransactionsView All Institutional Transactions CMRX Stock Analysis - Frequently Asked Questions How have CMRX shares performed this year? Chimerix's stock was trading at $0.9625 at the beginning of the year. Since then, CMRX shares have decreased by 7.5% and is now trading at $0.89. View the best growth stocks for 2024 here. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) released its quarterly earnings results on Wednesday, May, 1st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.04. Chimerix had a negative trailing twelve-month return on equity of 41.32% and a negative net margin of 25,337.96%. Who are Chimerix's major shareholders? Top institutional investors of Chimerix include Assenagon Asset Management S.A. (0.45%). Insiders that own company stock include Michael T Andriole, David Jakeman, Michelle Laspaluto, Fred A Middleton and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX) and Inovio Pharmaceuticals (INO). This page (NASDAQ:CMRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
